[Multiple myeloma of the IgD-lambda type invading CNS].
A 52-year-old woman was admitted to the gynecological department of our hospital on July 29, 2002 because of a right lower abdominal mass. She has been suffering from pain in the right leg and inguinal area for a month before coming to the hospital. She was found to have pancytopenia and high serum levels of LDH and IgD. A bone marrow examination showed 63.8% of plasma cells and serum immunoelectrophoresis showed M-protein of the IgD-lambda type. She was diagnosed as having multiple myeloma and transferred to our department. VAD therapy was started from August 22. Although the plasma cells in the bone marrow almost disappeared, the right lower abdominal mass remained and a new mass appeared on the right frontal chest wall after two courses of the treatment. Combination chemotherapy with vincristine, ranimustine, melphalan, and dexamethasone (ROAD) was started on November 1. This was followed with thalidomide and radiation therapy of the right inguinal region was added. On December 16th, she suddenly experienced speech disturbance, nausea and the disturbance of consciousness. Examination of her cerebrospinal fluid showed 368/microl mononuclear cells with 93% plasma cells. The plasma cells disappeared after the 6th intrathecal injection with MTX and prednisolone and the chemotherapy was resumed. One month later, CNS relapse was apparent followed by generalized spread of the tumor mass, and she died on March 17, 2003.
Kitamura
Kana
K
Division of 1st Internal Medicine, Department of Internal Medicine, Nihon University School of Medicine.
Takeuchi
Jin
J
Kanbe
Emiko
E
Oka
Hideaki
H
Saiki
Minoru
M
Aikawa
Shingo
S
Kura
Yoshimasa
Y
Hatta
Yoshihiro
Y
Yamazaki
Tetsuo
T
Ito
Takeyoshi
T
Sawada
Umihiko
U
Horie
Takashi
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007072:Immunoglobulin D / Q000097:blood; D007278:Injections, Spinal; D016898:Interferon-alpha / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D009194:Myeloma Proteins / Q000032:analysis; D009361:Neoplasm Invasiveness; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D013792:Thalidomide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D015415:Biomarkers; D007072:Immunoglobulin D; D016898:Interferon-alpha; D009194:Myeloma Proteins; D009607:Nitrosourea Compounds; C085016:multiple myeloma M-proteins; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D011239:Prednisolone; D008558:Melphalan; D008727:Methotrexate